

研究開発部門

Department of Research and Development

複雑系解析分野

Complex Biosystem Research

教授 中川 嘉 Nakagawa Yoshimi

◆ 研究概要

- 1) 糖・脂質代謝を制御する転写因子の機能解析
- 2) 細胞間、組織間連関による栄養代謝調節の解明
- 3) 和漢薬による生活習慣病治療の評価
- 4) 睡眠異常が引き起こす生活習慣病発症メカニズムの解明
- 5) 統合オミックス解析を用いた情報科学的解析の確立

◆ 原著

- 1) Matsuzaka T, Kuba M, Koyasu S, Yamamoto Y, Motomura K, Arulmozhiraja S, Ohno H, Sharma R, Shimura T, Okajima Y, Han SI, Aita Y, Mizunoe Y, Osaki Y, Iwasaki H, Yatoh S, Suzuki H, Sone H, Takeuchi Y, Yahagi N, Miyamoto T, Sekiya M, Nakagawa Y, Ema M, Takahashi S, Tokiwa H, Shimano H. Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice. *Hepatology*. 2020 May; 71(5): 1609-17. doi: 10.1002/hep.30953.
- 2) Ma Y, Sekiya M, Kainoh K, Matsuda T, Iwasaki H, Osaki Y, Sugano Y, Suzuki H, Takeuchi Y, Miyamoto T, Yahagi N, Nakagawa Y, Matsuzaka T, Shimano H. Transcriptional co-repressor CtBP2 orchestrates epithelial-mesenchymal transition through a novel transcriptional holocomplex with OCT1. *Biochem Biophys Res Commun*. 2020 Mar 5; 523(2): 354-7. doi: 10.1016/j.bbrc.2019.12.070.
- 3) Kawasaki M, Kambe A, Yamamoto Y, Arulmozhiraja S, Ito S, Nakagawa Y, Tokiwa H, Nakano S, Shimano H. Elucidation of Molecular Mechanism of a Selective PPAR α Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations. *Int J Mol Sci*. 2020 Jan 6; 21(1): 361. doi: 10.3390/ijms21010361.
- 4) Mizunoe Y, Kobayashi M, Hoshino S, Tagawa R, Itagawa R, Hoshino A, Okita N, Sudo Y, Nakagawa Y, Shimano H, Higami Y. Cathepsin B overexpression induces degradation of perilipin 1 to cause lipid metabolism dysfunction in adipocytes. *Sci Rep*. 2020 Jan 20; 10(1): 634. doi: 10.1038/s41598-020-57428-6.
- 5) Hoshino S, Kobayashi M, Tagawa R, Konno R, Abe T, Furuya K, Miura K, Wakasawa H, Okita N, Sudo Y, Mizunoe Y, Nakagawa Y, Nakamura T, Kawabe H, Higami Y. WWP1 knockout in mice exacerbates obesity-related phenotypes in white adipose tissue but improves whole-body glucose metabolism. *FEBS Open Bio*. 2020 Mar; 10(3): 306-10. doi: 10.1002/2211-5463.12795.
- 6) Satoh A, Han SI, Araki M, Nakagawa Y, Ohno H, Mizunoe Y, Kumagai K, Murayama Y, Osaki Y, Iwasaki H, Sekiya M, Konishi M, Itoh N, Matsuzaka T, Sone H, Shimano H. CREBH Improves Diet-Induced Obesity, Insulin Resistance, and Metabolic Disturbances by FGF21-Dependent and FGF21-Independent Mechanisms. *iScience*. 2020 Mar 27; 23(3): 100930. doi: 10.1016/j.isci.2020.100930.
- 7) Kobayashi M, Uta S, Otsubo M, Deguchi Y, Tagawa R, Mizunoe Y, Nakagawa Y, Shimano H, Higami Y. Srebp-1c/Fgf21/Pgc-1 α Axis Regulated by Leptin Signaling in Adipocytes-Possible Mechanism of Caloric Restriction-Associated Metabolic Remodeling of White Adipose Tissue. *Nutrients*. 2020 Jul 10; 12(7): 2054. doi: 10.3390/nu12072054.
- 8) Lim HY, Wang W, Nakagawa Y, Pierzchala-Koziec K. Editorial: The Endocrine Regulation of Systemic Energy Homeostasis Under Physiological and Pathological Conditions. *Front Physiol*. 2020 Oct 29; 11: 602942. doi: 10.3389/fphys.2020.602942.
- 9) Nakagawa Y, Wang Y, Han SI, Okuda K, Oishi A, Yagishita Y, Kumagai K, Ohno H, Osaki Y, Mizunoe Y, Araki M, Murayama Y, Iwasaki H, Konishi M, Itoh N, Matsuzaka T, Sone H, Yamada N, Shimano H. Enterohepatic Transcription

Factor CREB3L3 Protects Atherosclerosis via SREBP Competitive Inhibition. *Cell Mol Gastroenterol Hepatol.* 2020 Nov 24; 11(4):949-71. doi: 10.1016/j.jcmgh.2020.11.004.

- 10) Osawa T, Fujihara K, Harada Yamada M, Yamamoto M, Kitazawa M, Matsubayashi Y, Iwanaga M, Yamada T, Seida H, Kodama S, Nakagawa Y, Shimano H, Sone H. Severity of hypertension as a predictor of initiation of dialysis among study participants with and without diabetes mellitus. *J Investig Med.* 2020 Dec 18; 69(3) :424-9. doi: 10.1136/jim-2020-001489.

◆ **総 説**

- 1) 中川 嘉, 島野 仁. 肝臓の異常脂肪蓄積. *糖尿病プラクティス.* 2020 Jul; 37(4): 726-732.

◆ **学会報告**

- 1) 中川嘉, 王雨農, 韓松伊, 水之江雄平, 荒木雅弥, 関谷元博, 松坂賢, 島野仁. 腸肝転写因子CREBHはSREBPの活性を制御し, 動脈硬化発症を抑制する. 第63回日本糖尿病学会年次学術集会; 2020 Oct 5-16; 滋賀(オンライン).